Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications.
Advaita Acarya SinghOfentse Jacob PooeLusisizwe KweziTherese Lotter-StarkStoyan H StoychevKabamba AlexandraIsak GerberJinal N BhimanJuan VorsterMichael PaulyLarry ZeitlinKevin WhaleyLukas MachHerta SteinkellnerLynn MorrisTsepo Lebiletsa TsekoaRachel ChikwambaPublished in: Scientific reports (2020)
Broadly neutralising antibodies (bNAbs) against human immunodeficiency virus type 1 (HIV-1), such as CAP256-VRC26 are being developed for HIV prevention and treatment. These Abs carry a unique but crucial post-translational modification (PTM), namely O-sulfated tyrosine in the heavy chain complementarity determining region (CDR) H3 loop. Several studies have demonstrated that plants are suitable hosts for the generation of highly active anti-HIV-1 antibodies with the potential to engineer PTMs. Here we report the expression and characterisation of CAP256-VRC26 bNAbs with posttranslational modifications (PTM). Two variants, CAP256-VRC26 (08 and 09) were expressed in glycoengineered Nicotiana benthamiana plants. By in planta co-expression of tyrosyl protein sulfotransferase 1, we installed O-sulfated tyrosine in CDR H3 of both bNAbs. These exhibited similar structural folding to the mammalian cell produced bNAbs, but non-sulfated versions showed loss of neutralisation breadth and potency. In contrast, tyrosine sulfated versions displayed equivalent neutralising activity to mammalian produced antibodies retaining exceptional potency against some subtype C viruses. Together, the data demonstrate the enormous potential of plant-based systems for multiple posttranslational engineering and production of fully active bNAbs for application in passive immunisation or as an alternative for current HIV/AIDS antiretroviral therapy regimens.
Keyphrases
- antiretroviral therapy
- human immunodeficiency virus
- hiv aids
- hiv infected
- hiv positive
- hiv infected patients
- poor prognosis
- hepatitis c virus
- hiv testing
- copy number
- magnetic resonance
- binding protein
- protein protein
- single cell
- electronic health record
- contrast enhanced
- cell therapy
- artificial intelligence
- magnetic resonance imaging
- mesenchymal stem cells